United Kingdom · Question · Written question
UIN 10140
Tirzepatide
Original
Introduced
21 October 2024
Last action
30 October 2024 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
30 October 2024
Summary
To ask the Secretary of State for Health and Social Care, with reference to his Department's press release entitled Landmark collaboration with largest pharmaceutical company, published on 14 October 2024, how many times will a patient be allowed to take
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
21 October 2024
Written question
To ask the Secretary of State for Health and Social Care, with reference to his Department's press release entitled Landmark collaboration with largest pharmaceutical company, published on 14 October 2024, how many times will a patient be allowed to take
Source: Commons
30 October 2024
Answer
As announced on 14 October 2024, the SURMOUNT-REAL clinical trial of tirzepatide, brand name Mounjaro, is being developed between Health Innovation Manchester, The University of Manchester, and Eli Lilly and Company, with further details about the study t...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2024-10-21/10140
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1735663
- uk · wq-1735663 · source updated 30 October 2024